Botulinum Toxin in Raynaud's Phenomenon

Description

Raynaud's Phenomenon (RP) is the most common vasospastic disorder encountered by hand surgeons with an estimated prevalence of 5% in the general population. It's manifestations are broad, and can range from minor to severe. Sometimes it can be refractory to treatments. The goal of this study is to evaluate the efficacy of Botulinum toxin (BT) in the treatment of treatment refractory RP by objective and subjective measures.

Conditions

Raynaud Phenomenon

Talk to us

Study Overview

On this page

Study Details

Study overview

Raynaud's Phenomenon (RP) is the most common vasospastic disorder encountered by hand surgeons with an estimated prevalence of 5% in the general population. It's manifestations are broad, and can range from minor to severe. Sometimes it can be refractory to treatments. The goal of this study is to evaluate the efficacy of Botulinum toxin (BT) in the treatment of treatment refractory RP by objective and subjective measures.

Double Blind RCT to Evaluate the Effect of Botulinum Toxin in Raynaud Phenomenon

Botulinum Toxin in Raynaud's Phenomenon

Condition
Raynaud Phenomenon
Intervention / Treatment

-

Contacts and Locations

Atlanta

Emory University Hospital, Atlanta, Georgia, United States, 30322

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age 18 or older
  • * Patients with moderate to severe RP that is not controlled after 3 months of standard medical therapy as prescribed by a Rheumatologist, or severe RP with evidence of tissue loss.
  • * Patients under the age of 18
  • * Patients who have previously undergone treatment with BT for RP within the past year
  • * Patients with active infection at the treatment site (active infection defined as cellulitis, purulence, fever, chills, or presence of elevated inflammatory markers, ie. WBC, ESR, CRP)
  • * Patients who have undergone prior digital sympathectomy surgery for RP
  • * Patients who have recently altered their medical regimen for RP within the past 4 weeks
  • * Patients with allergy or contraindication to BT injection

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Emory University,

Paul A Ghareeb, MD, PRINCIPAL_INVESTIGATOR, Emory University

Study Record Dates

2024-12